Higher levels of von Willebrand Factor in hospitalised patient plasma provides an explanation for the association of ABO blood group and secretor status with COVID19 severity

Tosti J Mankelow; Allison Blair; David T Arnold; Fergus W Hamilton; Kathleen M Gillespie; David J Anstee; Ash M Toye

doi:10.1111/tme.12860

Higher levels of von Willebrand Factor in hospitalised patient plasma provides an explanation for the association of ABO blood group and secretor status with COVID19 severity

Tosti J Mankelow^*, Allison Blair, David T Arnold, Fergus W Hamilton, Kathleen M Gillespie, David J Anstee, Ash M Toye^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate (Academic Journal) › peer-review

2 Citations (Scopus)

85 Downloads (Pure)

Abstract

[No abstract]

Original language	English
Pages (from-to)	261-262
Number of pages	2
Journal	Transfusion Medicine
Volume	32
Issue number	3
Early online date	24 Mar 2022
DOIs	https://doi.org/10.1111/tme.12860
Publication status	E-pub ahead of print - 24 Mar 2022

Bibliographical note

Funding Information:
This work was supported by the National Institute for Health Research Blood and Transplant Research Unit (NIHR BTRU) in Red Cell Products (IS‐BTU‐1214‐10032) and the Department of Health (England) (National Health Service Blood and Transplant research and development grant ‐ WP15‐04). The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. The authors apologise that not all references relevant to this letter could be cited because of reference number limits imposed by the journal. The authors dedicate this manuscript to the memory of Professor David Anstee who, early in the pandemic (February 2020), had the foresight to initiate our investigation into secretor status alongside ABO group in association with COVID19 disease severity and who then went on to make the link with VWF that led to this study. Although Prof Anstee approved the content presented in the manuscript, he sadly died before submission. 5

Funding Information:
This work was supported by the National Institute for Health Research Blood and Transplant Research Unit (NIHR BTRU) in Red Cell Products (IS-BTU-1214-10032) and the Department of Health (England) (National Health Service Blood and Transplant research and development grant - WP15-04). The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. The authors apologise that not all references relevant to this letter could be cited because of reference number limits imposed by the journal. The authors dedicate this manuscript to the memory of Professor David Anstee who, early in the pandemic (February 2020), had the foresight to initiate our investigation into secretor status alongside ABO group in association with COVID19 disease severity5 and who then went on to make the link with VWF that led to this study. Although Prof Anstee approved the content presented in the manuscript, he sadly died before submission.

Research Groups and Themes

Academic Respiratory Unit

Access to Document

10.1111/tme.12860

Full-text PDF (accepted author manuscript)
This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Wiley at https://doi.org/10.1111/tme.12860. Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 207 KB

Handle.net

Persistent link

Cite this

Mankelow, T. J., Blair, A., Arnold, D. T., Hamilton, F. W., Gillespie, K. M., Anstee, D. J., & Toye, A. M. (2022). Higher levels of von Willebrand Factor in hospitalised patient plasma provides an explanation for the association of ABO blood group and secretor status with COVID19 severity. Transfusion Medicine, 32(3), 261-262. Advance online publication. https://doi.org/10.1111/tme.12860

@article{e7c6374300b445f5b77886b93d1c39de,

title = "Higher levels of von Willebrand Factor in hospitalised patient plasma provides an explanation for the association of ABO blood group and secretor status with COVID19 severity",

abstract = "[No abstract]",

author = "Mankelow, {Tosti J} and Allison Blair and Arnold, {David T} and Hamilton, {Fergus W} and Gillespie, {Kathleen M} and Anstee, {David J} and Toye, {Ash M}",

note = "Funding Information: This work was supported by the National Institute for Health Research Blood and Transplant Research Unit (NIHR BTRU) in Red Cell Products (IS‐BTU‐1214‐10032) and the Department of Health (England) (National Health Service Blood and Transplant research and development grant ‐ WP15‐04). The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. The authors apologise that not all references relevant to this letter could be cited because of reference number limits imposed by the journal. The authors dedicate this manuscript to the memory of Professor David Anstee who, early in the pandemic (February 2020), had the foresight to initiate our investigation into secretor status alongside ABO group in association with COVID19 disease severity and who then went on to make the link with VWF that led to this study. Although Prof Anstee approved the content presented in the manuscript, he sadly died before submission. 5 Funding Information: This work was supported by the National Institute for Health Research Blood and Transplant Research Unit (NIHR BTRU) in Red Cell Products (IS-BTU-1214-10032) and the Department of Health (England) (National Health Service Blood and Transplant research and development grant - WP15-04). The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. The authors apologise that not all references relevant to this letter could be cited because of reference number limits imposed by the journal. The authors dedicate this manuscript to the memory of Professor David Anstee who, early in the pandemic (February 2020), had the foresight to initiate our investigation into secretor status alongside ABO group in association with COVID19 disease severity5 and who then went on to make the link with VWF that led to this study. Although Prof Anstee approved the content presented in the manuscript, he sadly died before submission.",

year = "2022",

month = mar,

day = "24",

doi = "10.1111/tme.12860",

language = "English",

volume = "32",

pages = "261--262",

journal = "Transfusion Medicine",

issn = "0960-5592",

publisher = "Wiley-Blackwell",

number = "3",

}

Higher levels of von Willebrand Factor in hospitalised patient plasma provides an explanation for the association of ABO blood group and secretor status with COVID19 severity. / Mankelow, Tosti J; Blair, Allison; Arnold, David T et al.
In: Transfusion Medicine, Vol. 32, No. 3, 24.03.2022, p. 261-262.

Research output: Contribution to journal › Comment/debate (Academic Journal) › peer-review

TY - JOUR

T1 - Higher levels of von Willebrand Factor in hospitalised patient plasma provides an explanation for the association of ABO blood group and secretor status with COVID19 severity

AU - Mankelow, Tosti J

AU - Blair, Allison

AU - Arnold, David T

AU - Hamilton, Fergus W

AU - Gillespie, Kathleen M

AU - Anstee, David J

AU - Toye, Ash M

N1 - Funding Information: This work was supported by the National Institute for Health Research Blood and Transplant Research Unit (NIHR BTRU) in Red Cell Products (IS‐BTU‐1214‐10032) and the Department of Health (England) (National Health Service Blood and Transplant research and development grant ‐ WP15‐04). The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. The authors apologise that not all references relevant to this letter could be cited because of reference number limits imposed by the journal. The authors dedicate this manuscript to the memory of Professor David Anstee who, early in the pandemic (February 2020), had the foresight to initiate our investigation into secretor status alongside ABO group in association with COVID19 disease severity and who then went on to make the link with VWF that led to this study. Although Prof Anstee approved the content presented in the manuscript, he sadly died before submission. 5 Funding Information: This work was supported by the National Institute for Health Research Blood and Transplant Research Unit (NIHR BTRU) in Red Cell Products (IS-BTU-1214-10032) and the Department of Health (England) (National Health Service Blood and Transplant research and development grant - WP15-04). The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. The authors apologise that not all references relevant to this letter could be cited because of reference number limits imposed by the journal. The authors dedicate this manuscript to the memory of Professor David Anstee who, early in the pandemic (February 2020), had the foresight to initiate our investigation into secretor status alongside ABO group in association with COVID19 disease severity5 and who then went on to make the link with VWF that led to this study. Although Prof Anstee approved the content presented in the manuscript, he sadly died before submission.

PY - 2022/3/24

Y1 - 2022/3/24

N2 - [No abstract]

AB - [No abstract]

U2 - 10.1111/tme.12860

DO - 10.1111/tme.12860

M3 - Comment/debate (Academic Journal)

C2 - 35332587

SN - 0960-5592

VL - 32

SP - 261

EP - 262

JO - Transfusion Medicine

JF - Transfusion Medicine

IS - 3

ER -

Higher levels of von Willebrand Factor in hospitalised patient plasma provides an explanation for the association of ABO blood group and secretor status with COVID19 severity

Abstract

Bibliographical note

Research Groups and Themes

Access to Document

Handle.net

Fingerprint

Cite this